Payment overview · 2025
General Payments
$100.40
6 reported records · 5 companies
Healthcare provider profile · identity verified
Sakshi Pawa, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · TOMS RIVER, NJ · NPI 1508099722
Verified facts
What the public records show
CMS Open Payments records show Sakshi Pawa, M.D received $100.40 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.48 | 30.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.03 | 18.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.39 | 18.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.19 | 17.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.31 | 15.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $100.40 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $37.42 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 441 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 366 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 65 |
| Losartan Potassium | Losartan Potassium | 296 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 64 |
| Eliquis | Apixaban | 233 | 32 |
| Simvastatin | Simvastatin | 204 | 63 |
| Metformin Hcl | Metformin Hcl | 193 | 41 |
| Sertraline Hcl | Sertraline Hcl | 191 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 42 |
| Furosemide | Furosemide | 168 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 43 |
| Lisinopril | Lisinopril | 154 | 32 |
| Potassium Chloride | Potassium Chloride | 132 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 50 |
| Gabapentin | Gabapentin | 118 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 32 |
| Alprazolam | Alprazolam | 99 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 20 |
| Mirtazapine | Mirtazapine | 91 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 28 |
| Trazodone Hcl | Trazodone Hcl | 83 | suppressed |
| Carvedilol | Carvedilol | 78 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 20 |
| Valsartan | Valsartan | 66 | suppressed |
| Famotidine | Famotidine | 62 | 11 |
| Glipizide | Glipizide | 62 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 14 |
| Allopurinol | Allopurinol | 53 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 50 | 17 |
| Omeprazole | Omeprazole | 49 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 47 | suppressed |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Nifedipine Er | Nifedipine | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 24 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 39 |
| Metformin Hcl Er | Metformin Hcl | 44 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 41 | 11 |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Prednisone | Prednisone | 32 | 24 |
| Latanoprost | Latanoprost | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 26 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Nystatin | Nystatin | 23 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nystop | Nystatin | 22 | 11 |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 20 |
| Finasteride | Finasteride | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $100.40 · 6 records | Novo Nordisk Inc | KISUNLA, Kerendia, Ozempic, REXULTI, Rybelsus, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error